Abacavir succinate

This classification denotes a reverse transcriptase inhibitor, in succinate form, with the molecular formula C14H18N6O.C4H6O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 40FH6D8CHK, chemically known as butanedoic acid, compd. with (1s,4r)-4-(2-amino-6-(cyclopropylamino)-9h-purin-9-yl)-2-cyclopentene-1-methanol (1:1) but more generally known as abacavir succinate, which bears US NIH Compound Identifier 65139. The base compound, abacavir, also appears in sulfate form, and is sometimes combined with lamivudine and zidovudine. European Medicines Agency schedules Abacavir succinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25392. Most nations, for tariff and trade purposes, schedule abacavir succinate under HS 29335995 and SITC 51576. As of Q4 2014, ABACAVIR SUCCINATE remains US FDA's Preferred Term for this commodity. Abacavir succinate bears US NLM identifiers UMLS ID C2346706 and NCI Concept Code C71608. SMILES: C1NC2C(NC(NC2N1[C@@H]3C[C@@H](C=C3)CO)N)NC4CC4.C(CC(=O)O)C(=O)O.